Separate Antiaging Trials of Rapamycin and Metformin
AgelessRx states that PEARL was the first nationwide telemedicine study and one of the largest intervention trials in Longevity. The human trial will pave the way for rapamycin’s introduction to the Longevity Market. PEARL is a $600,000.00 trial conducted with the University of California. In a double-blind, controlled, placebo-controlled, randomized trial, they will assess the safety and efficacy of rapamycin on 200 healthy adults.
Telemedicine will be used to screen for eligibility. Patients who are eligible must be aged 50-85, of any gender, and any ethnicity. They should also be in good health with well-managed chronic diseases.
TAME is an independent $75 million trial that aims to evaluate Metformin for its Longevity properties. TAME’s primary endpoint is a composite of stroke, heart failure dementia, myocardial ischemia, cancer, and death. Instead of attempting to cure a single endpoint, the trial will aim to delay its onset, increasing the number of years that subjects are in good health. The TAME trial will be funded by a $40 million donation and a 35 million NIH grant.
Source:
